149
0 Kommentare
DONESTA safety study for menopause completes treatment phase and advances to data management & reporting phase - Seite 3
ESTELLE and DONESTA are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.
Lesen Sie auch
Important information
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of
forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project",
"target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties,
and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the
forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive press releases by email or follow us on social media: LinkedIn • X • Facebook |